NTM in Oncology: Dual Beta-Lactam Signals Warrant Study

This single-center cohort characterizes nontuberculous mycobacterial epidemiology, susceptibility, and real-world treatment (including meropenem-based dual beta-lactam therapy) in cancer patients, an area with sparse pharmacotherapy data.

nontuberculous mycobacteriaMycobacterium avium complexMycobacterium abscessusmeropenemceftarolineimipenem-cilastatindual beta-lactambedaquilineoncologyretrospective cohortantimicrobial stewardshipOPAT Infectious Disease / Antimicrobials

Background Information

NTM infections in cancer patients demand complex treatment approaches.

Nontuberculous mycobacteria (NTM) infections are increasing, and oncology patients represent a unique population at risk. 93 patients were studied, with Mycobacterium avium complex and Mycobacterium abscessus as common pathogens. 53% received therapy, often requiring regimen modifications. The findings highlight treatment challenges in oncology patients, noting dual β-lactam therapy's role. Limitations include the single-center retrospective design. NTM infections in oncology require complex, adaptive treatment strategies.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Pasikhova Y, Snyder M, Morrison A, Handley G, Syed M, Cannella AP

Citation: Pasikhova Y, Snyder M, Morrison A, et al. Nontuberculous Mycobacterial Infections at a National Cancer Institute-Designated Comprehensive Cancer Center in Florida. Open forum infectious diseases. 2026;13(8):ofag467. doi:10.1093/ofid/ofag467

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →